Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

US market

This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for gene therapy Zolgensma in SMA

Novartis makes case for gene therapy Zolgensma in SMA

strategy. That came after it evaluated first-to-market SMA gene therapy Spinraza and concluded that the Biogen marketed drug is overpriced. ... Spinraza has been on the US market since 2016, and comes in at a list price $750, 000 for the initial year and

Latest news

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    developing it for the US market. ... It is being fuelled by the major unmet medical needs in China, systemic regulatory reforms that are accelerating new drug innovation and deepening market access.”.

  • Biogen’s Spinraza overpriced, says ICER Biogen’s Spinraza overpriced, says ICER

    Spinraza has been on the US market since 2016, and has since “dramatically improved the lives of children with SMA and that of their families,” said ICER’s chief medical officer ... In his latest move, the US president looks to once again take aim

  • Setback for Vertex’s cystic fibrosis challenger Proteostasis Setback for Vertex’s cystic fibrosis challenger Proteostasis

    The chosen candidate is then expected to gain approval in the US market in the first half 2020, followed by Europe in the first half 2021. ... It is increasing its forecast peak market share of a Vertex triple reaching the market in the US and EU to 85%

  • Quick Change Quick Change

    What bird feathers can teach us about adapting to the market. ... Its current practice is pretty typical of the industry: it segments the market according to disease stage.

  • Allergy Tx hit hard as birch pollen product stumbles Allergy Tx hit hard as birch pollen product stumbles

    the first product of its kind in the $2bn US allergy market and a phase 1 peanut allergy candidate. ... reiterated his determination to bring the product to market.

More from news
Approximately 1 fully matching, plus 762 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    The chosen candidate is then expected to gain approval in the US market in the first half of 2020, followed by Europe in the first half of 2021. ... Y. Katherine Xu, an analyst at William Blair, forecast peak annual sales of $10.2bn, up from $8.9bn

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Almost all sales come from the US market, mainly because of supply constraints for Cinryze in recent years, something that the combined company will aim to address. ... In the long term, a US market share of 10% of the number of patients treated, or

  • Is China ready for a pharmaceutical gold rush?

    Rapidly growing sector. The US alone holds over 45% of the global pharmaceutical market. ... Indeed, BMS will pitch Opdivo at half the US list price, determining the true value of market access.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    For the US market, this would formerly have been seen as an outrageous idea, and US pharma CEOs and industry lobby group PhRMA have opposed the move. ... These battles over pricing and access in the US market remain among the biggest priorities for

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    So how long before China eclipses the European market as the second most important behind the US? ... Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

  • New faces at 11 London, ramarketing and MSL New faces at 11 London, ramarketing and MSL

    The new office in Cambridge, Massachusetts, will give ramarketing a presence in the growing pharma and biotech hub and a foothold in the US market, allowing it to locally service its ... Emma’s insight into the global life sciences sector means she

  • Pharma industry appointments Pharma industry appointments

    Prior to this, Jenkins spent 17 years at GlaxoSmithKline (GSK) in the UK and US. ... UK. Vu, whose new post will see him further expand Concept’s presence in the US market, joins the company with over 15 years’ experience in both business development

  • Open Health creates new role Open Health creates new role

    Joining the agency with twenty years’ biopharmaceutical industry experience, Jones’ expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications offering.

  • Amra appoints new VP of North American sales Jeremy Edwards Amra appoints new VP of North American sales Jeremy Edwards

    With more than 20 years’ experience in the clinical development industry, Edwards joins the company after spending five years as vice president and general manager of the US operations for Exco ... expand the US market.”.

More from appointments
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

  • Emotional Recognition using Facial Analysis

    According to psychologists, a lot of emotional information can be drawn from our facial expressions, which is valuable to us as market researchers as we are interested in the emotional responses

  • Genetic counsellors: the new healthcare influencers?

    There are more than  70, 000  different genetic testing products available on the US market in 2018 with 10 new tests entering the market daily. ... The prolific number of direct to consumer genetic tests on the market has also heightened confusion for

  • Shining brighter than ever

    They have helped us to really highlight all of the services that we offer and show that we are a genuine full-service provider.”. ... Our workshop helped us to unearth insights about the company and its market that led to the development of a strong

  • Hanson Zandi

    MARKET ACCESS TOOLS. Our range of market access tools includes Fast-TRAQ and Budget Impact Models. ... Market Access Strategy Associate Director. Great work, look forward to implementing this in the Pacrim.

  • A New Managing Director Appointed for Lighthouse Medical Communications US

    growth of the group in the US market. ... client side, made him the ideal choice to head the Lighthouse Communications team in the US.

More from PMHub
Approximately 0 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia